Corcept Therapeutics (CORT) Amortization of Deferred Charges (2016 - 2021)
Corcept Therapeutics (CORT) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $508000.0 as the latest value for Q4 2021.
- Quarterly Amortization of Deferred Charges rose 4.96% to $508000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2021, up 16.53% year-over-year, with the annual reading at $2.0 million for FY2021, 16.53% up from the prior year.
- Amortization of Deferred Charges hit $508000.0 in Q4 2021 for Corcept Therapeutics, up from $502000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $508000.0 in Q4 2021 to a low of $3000.0 in Q3 2017.
- Historically, Amortization of Deferred Charges has averaged $345933.3 across 4 years, with a median of $385000.0 in 2020.
- Biggest five-year swings in Amortization of Deferred Charges: tumbled 40.0% in 2017 and later skyrocketed 45.78% in 2020.
- Year by year, Amortization of Deferred Charges stood at $3000.0 in 2017, then surged by 10966.67% to $332000.0 in 2019, then surged by 45.78% to $484000.0 in 2020, then increased by 4.96% to $508000.0 in 2021.
- Business Quant data shows Amortization of Deferred Charges for CORT at $508000.0 in Q4 2021, $502000.0 in Q3 2021, and $496000.0 in Q2 2021.